NCT07604753 Validation of the CIDI 5.0 Against the SCID-5 for Lifetime Mental Disorders
| NCT ID | NCT07604753 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Hong Kong |
| Condition | Major Depressive Disorder (MDD) |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2025-05-14 |
| Primary Completion | 2028-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2025-05-14 with a primary completion date of 2028-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The World Health Organization Composite International Diagnostic Interview (CIDI) is a fully structured diagnostic tool designed for lay interviewers to assess the prevalence of mental and substance use disorders. Earlier versions, such as the CIDI 3.0, demonstrated acceptable individual-level concordance with clinical assessments based on DSM-IV criteria (Haro et al. 2006). The latest iteration (CIDI 5.0) has been updated to operationalize DSM-5 criteria. Recent evidence from a large-scale, community-based national study in Qatar suggests that under DSM-5 criteria (Khaled et al. 2024), after recalibration, the CIDI 5.0 maintains high specificity (91.9% for MDD, 94.7% for GAD, and 85.5% for PTSD). Sensitivity suggested CIDI diagnoses aligned closely with clinical "gold standard" diagnoses (51.5% for MDD, 50.7% for GAD, and 77.3% for PTSD). Despite the evidence from Qatar, there remains a lack of evidence regarding the validity of the CIDI 5.0 in population-based studies. Therefore, this study aims to evaluate the diagnostic validity of the CIDI 5.0 for Lifetime MDD, GAD, and PTSD, using the Structured Clinical Interview for DSM-5 (SCID-5) as the definitive clinical gold standard.
Eligibility Criteria
Inclusion Criteria: * All household members aged 18 years old and over are randomly sampled from the Census and Statistics Department List of Quarters * Live in the address sampled from the Census and Statistics Department List of Quarters * Reside in Hong Kong for at least six months in the past year * Able to read and communicate in Chinese or English * Without linguistic or cognitive difficulties Exclusion Criteria: * Domestic workers
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07604753 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Major Depressive Disorder (MDD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07604753 currently recruiting?
Yes, NCT07604753 is actively recruiting participants. Contact the research team at yoonak@hku.hk for enrollment information.
Where is the NCT07604753 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong.
Who is sponsoring the NCT07604753 clinical trial?
NCT07604753 is sponsored by The University of Hong Kong. The trial plans to enroll 300 participants.